Clinically, combining RT with EGFR TKIs may be more beneficial, as shown by the REFRACT study, which reported improved progression-free and overall survival, particularly in Asian patients with locally advanced EGFRm-NSCLC [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.